Dallas VA Medical Center MS Center, Dallas, Texas (Ms O'Leary); Long Ridge Medical Center, Neurology, Greenwich Hospital, Stamford, Connecticut (Ms Brugger); Rocky Mountain MS Clinic, Salt Lake City, Utah (Mr Wallentine); The Regional MS Center & The Center for Neurological Disorders, Milwaukee, Wisconsin (Ms Sershon); University of Alabama at Birmingham, Birmingham, Alabama (Ms Goff); Biogen, Cambridge, Massachusetts (Mss Saldana-King and Beavin; Drs Avila and Rutledge); Novant MS Care Center, Charlotte, North Carolina (Ms Moore).
Shirley O'Leary, MS, APN-C, MSCN, has practiced as a provider, subinvestigator/researcher, and neurology infusion manager for 7 years at the MS Center of Excellence at the Dallas VA Medical Center. She has 27 years of experience in the area of multiple sclerosis (MS) and has authored articles, given numerous invited talks, and is a longstanding member of the International Organization of MS Nurses.
J Infus Nurs. 2023;46(6):347-359. doi: 10.1097/NAN.0000000000000519.
Natalizumab (TYSABRI®) was the first high-efficacy monoclonal antibody disease-modifying therapy (DMT) approved as a monotherapy for the treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. Because natalizumab is administered by intravenous infusion, infusion nurses play a key role in the care of natalizumab-treated patients. In the 16 years since approval, substantial data have been gathered on the long-term, real-world effectiveness and safety of natalizumab. This article provides a synopsis of this data, as well as practical information for optimizing patient care. This includes information on strategies to mitigate the risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients, natalizumab use during pregnancy, and use with vaccines. It also includes guidance on the preparation and administration of natalizumab and monitoring of natalizumab-treated patients.
那他珠单抗（TYSABRI®）是首个被批准用于治疗成人复发型多发性硬化症（MS）的高效单克隆抗体疾病修正治疗药物（DMT），包括临床孤立综合征、复发缓解型 MS 和活动性继发进展型 MS。由于那他珠单抗是通过静脉输注给药的，输注护士在那他珠单抗治疗患者的护理中起着关键作用。自批准以来的 16 年中，已经收集了大量关于那他珠单抗的长期、真实世界的有效性和安全性数据。本文对这些数据进行了总结，并提供了优化患者护理的实用信息。这包括了降低那他珠单抗治疗患者进行性多灶性白质脑病风险的策略、那他珠单抗在怀孕期间的使用以及与疫苗联合使用的信息。它还包括了那他珠单抗的准备和管理以及那他珠单抗治疗患者监测的指导。
